Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Satisfy DSM-IV criteria for schizophrenia as established by SCID-CV~* The patient must agree to a voluntary hospitalization duration of 31 days minimum at the start of the treatment~* If female, must not be pregnant, or must be incapable of conceiving or be taking steps to prevent conception~Exclusion Criteria:~* The patient has used an investigational drug within the past 30 days~* The patient has participated in a previous study of this compound

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Lurasidone (Type: EXPERIMENTAL): 80 mg AM dosing once daily
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).